Thinly traded nano cap Summit Therapeutics (NASDAQ:SMMT) is up 11% premarket on increased volume in response to its announcement that it has been award a $4.5M grant from a public/private partnership called CARB-X to support the development of new antibiotics to treat gonorrhoea.
$2M in initial funding will used to support the selection of a preclinical candidate, expected in H2. The remaining $2.5M will be awarded upon the achievement of certain development milestones.
The total amount should be sufficient to fund development through Phase 1.
you may also want to read
3 June 2018